Open Access
Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
Publication type: Journal Article
Publication date: 2019-03-01
Inorganic Chemistry
Abstract
After nearly 20 years of research on the use of ruthenium in the fight against cancer, only two Ru(III) coordination complexes have advanced to clinical trials. During this time, the field has produced excellent candidate drugs with outstanding in vivo and in vitro activity; however, we have yet to find a ruthenium complex that would be a viable alternative to platinum drugs currently used in the clinic. We aimed to explore what we have learned from the most prominent complexes in the area, and to challenge new concepts in chemical design. Particularly relevant are studies involving NKP1339, NAMI-A, RM175, and RAPTA-C, which have paved the way for current research. We explored the development of the ruthenium anticancer field considering that the mechanism of action of complexes no longer focuses solely on DNA interactions, but explores a diverse range of cellular targets involving multiple chemical strategies.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Molecules
13 publications, 8.9%
|
|
|
Dalton Transactions
10 publications, 6.85%
|
|
|
Pharmaceutics
6 publications, 4.11%
|
|
|
Inorganic Chemistry
6 publications, 4.11%
|
|
|
Pharmaceuticals
5 publications, 3.42%
|
|
|
Inorganics
4 publications, 2.74%
|
|
|
Journal of Inorganic Biochemistry
4 publications, 2.74%
|
|
|
Polyhedron
4 publications, 2.74%
|
|
|
Journal of Organometallic Chemistry
4 publications, 2.74%
|
|
|
Inorganica Chimica Acta
4 publications, 2.74%
|
|
|
ChemMedChem
4 publications, 2.74%
|
|
|
International Journal of Molecular Sciences
3 publications, 2.05%
|
|
|
Coordination Chemistry Reviews
3 publications, 2.05%
|
|
|
Inorganic Chemistry Communication
3 publications, 2.05%
|
|
|
ChemBioChem
3 publications, 2.05%
|
|
|
Reviews in Inorganic Chemistry
3 publications, 2.05%
|
|
|
RSC Advances
3 publications, 2.05%
|
|
|
Chemical Science
3 publications, 2.05%
|
|
|
Journal of Coordination Chemistry
3 publications, 2.05%
|
|
|
Mendeleev Communications
2 publications, 1.37%
|
|
|
Organometallics
2 publications, 1.37%
|
|
|
Frontiers in Chemistry
2 publications, 1.37%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 1.37%
|
|
|
Journal of Molecular Structure
2 publications, 1.37%
|
|
|
Applied Organometallic Chemistry
2 publications, 1.37%
|
|
|
New Journal of Chemistry
2 publications, 1.37%
|
|
|
Metallomics
2 publications, 1.37%
|
|
|
Journal of Medicinal Chemistry
1 publication, 0.68%
|
|
|
Journal of Chemical Physics
1 publication, 0.68%
|
|
|
Antioxidants and Redox Signaling
1 publication, 0.68%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
37 publications, 25.34%
|
|
|
MDPI
34 publications, 23.29%
|
|
|
Royal Society of Chemistry (RSC)
19 publications, 13.01%
|
|
|
Wiley
12 publications, 8.22%
|
|
|
American Chemical Society (ACS)
11 publications, 7.53%
|
|
|
Springer Nature
8 publications, 5.48%
|
|
|
Taylor & Francis
6 publications, 4.11%
|
|
|
Walter de Gruyter
4 publications, 2.74%
|
|
|
Frontiers Media S.A.
3 publications, 2.05%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
2 publications, 1.37%
|
|
|
Oxford University Press
2 publications, 1.37%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 1.37%
|
|
|
AIP Publishing
1 publication, 0.68%
|
|
|
Mary Ann Liebert
1 publication, 0.68%
|
|
|
Portland Press
1 publication, 0.68%
|
|
|
Hindawi Limited
1 publication, 0.68%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.68%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.68%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
146
Total citations:
146
Citations from 2025:
16
(10.95%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Coverdale J., Laroiya Mccarron T., Romero Canelón I. Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates? // Inorganics. 2019. Vol. 7. No. 3. p. 31.
GOST all authors (up to 50)
Copy
Coverdale J., Laroiya Mccarron T., Romero Canelón I. Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates? // Inorganics. 2019. Vol. 7. No. 3. p. 31.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3390/inorganics7030031
UR - https://doi.org/10.3390/inorganics7030031
TI - Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
T2 - Inorganics
AU - Coverdale, James
AU - Laroiya Mccarron, Thaisa
AU - Romero Canelón, Isolda
PY - 2019
DA - 2019/03/01
PB - MDPI
SP - 31
IS - 3
VL - 7
SN - 2304-6740
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Coverdale,
author = {James Coverdale and Thaisa Laroiya Mccarron and Isolda Romero Canelón},
title = {Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?},
journal = {Inorganics},
year = {2019},
volume = {7},
publisher = {MDPI},
month = {mar},
url = {https://doi.org/10.3390/inorganics7030031},
number = {3},
pages = {31},
doi = {10.3390/inorganics7030031}
}
Cite this
MLA
Copy
Coverdale, James, et al. “Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?.” Inorganics, vol. 7, no. 3, Mar. 2019, p. 31. https://doi.org/10.3390/inorganics7030031.